Trial reportPituitary2010
Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly.
Trial report in Pituitary, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00447499 (A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel), which is not on this map. Cited by 30 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
Who cites it
30 citing papers in PubMed, 5 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Evaluating home injection compared with healthcare-setting injection of somatostatin analogs: a systematic literature review.Endocrine · 2023Pooled it
- Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review.Advances in therapy · 2021Pooled it
- Improvement in Symptoms and Health-Related Quality of Life in Acromegaly Patients: A Systematic Review and Meta-Analysis.The Journal of clinical endocrinology and metabolism · 2021Pooled it
- Surgical interventions and medical treatments in treatment-naïve patients with acromegaly: systematic review and meta-analysis.The Journal of clinical endocrinology and metabolism · 2014Pooled it
- Expert consensus document: A consensus on the medical treatment of acromegaly.Nature reviews. Endocrinology · 2014Guideline
- Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands.Frontiers in endocrinology · 2021Trial
- Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide.The Journal of clinical endocrinology and metabolism · 2020Trial
- Sustained Activation of CLR/RAMP Receptors by Gel-Forming Agonists.International journal of molecular sciences · 2022Article
- Gel-forming antagonist provides a lasting effect on CGRP-induced vasodilation.Frontiers in pharmacology · 2022Article
- Results from ACROCOVID: an international survey on the care of acromegaly during the COVID-19 era.Endocrine · 2021Article
- Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO).Advances in therapy · 2020Article
- Article
- Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies.Advances in therapy · 2019Article
- A Consensus Statement on acromegaly therapeutic outcomes.Nature reviews. Endocrinology · 2018Review
- Monotherapy with lanreotide depot for acromegaly: long-term clinical experience in a pituitary center.Pituitary · 2016Article
- Attitudes and preferences in patients with acromegaly on long-term treatment with somatostatin analogues.Endocrine connections · 2016Article
- Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly.Pituitary · 2016Review
- Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly.European journal of endocrinology · 2016Observational
- Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.Current oncology reports · 2016Review
- Severe scalp hair loss in a female patient with acromegaly treated with lanreotide autogel after unsuccessful surgery.Clinical case reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Surgical resection is often not curative in patients with acromegaly and long-acting somatostatin analogues (lanreotide or octreotide) are often needed. This study assessed the efficacy and safety of self- or partner-administration of lanreotide in patients with acromegaly. This was a six-month, single-arm, open-label study conducted at 13 endocrinology clinics. Fifty-nine patients received deep subcutaneous lanreotide injections every 28 days. Twelve patients started on 120 mg lanreotide and forty-seven started on 90 mg lanreotide. At week 16, the dose was adjusted to 60, 90 or 120 mg based on insulin-like growth factor-1 (IGF-1) levels at week 12. Fifty-nine patients with acromegaly either switched from long-acting octreotide (switch; n = 33) or were somatostatin analogue treatment-naïve or not currently taking long-acting octreotide ("other"; n = 26). The key endpoints included the percentage of patients/partners able to self- or partner-inject lanreotide and those with normal IGF-1 or growth hormone (GH) levels at week 24/early termination. 100% of patients/partners correctly self- (n = 41) or partner-injected (n = 18) lanreotide by week 4. By week 24/early termination, IGF-1 levels were controlled in 93.7% of switch and 46.2% of "other" patients, while GH levels were controlled in 76.9% and 39.1% of patients, respectively. Both IGF-1 and GH were controlled in 73.1% of switch and 30.4% of "other" patients. Most switch patients (81%) reported they preferred lanreotide over long-acting octreotide for future use (P = 0.0001). Self- or partner-administration of lanreotide is generally well tolerated and associated with IGF-1 and GH control in many lanreotide-naïve patients with acromegaly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.